Drug treatment commissioning and market mechanisms with Alison Ritter

Drug treatment commissioning and market mechanisms with Alison Ritter

How do funding mechanisms impact the quality of drug treatment services? In this episode of 'Addiction Audio', Dr. Rob Calder sits down with Professor Alison Ritter to unpack her recent study on the effectiveness of market mechanisms in alcohol and drug treatment outcomes. Ritter's research delves into the Australian context, comparing non-government, competitively tendered services with government services that receive recurrent funding. She paints a vivid picture of the complexities involved, likening the funding arrangements to a bowl of spaghetti.

The discussion sheds light on why competitive tendering isn't always necessary and explores the burdens that come with recommissioning. One of the standout points is the potential for fixed-price tendering to elevate the quality of addiction treatment services. Ritter also touches on the difficulties in measuring outcomes within current commissioning structures and suggests that future research could estimate the costs of various procurement methods.

A key takeaway is the importance of planning future services in collaboration with different governments to address these complexities and improve care quality. This episode is a must-listen for anyone interested in the intricate workings of drug treatment commissioning and the quest for better outcomes.